Categories Health Care, Trending Stocks

Where do these companies stand in the COVID-19 vaccine race?

J&J plans to file for Emergency Use Authorization in the US in early February

After the struggle with the COVID-19 pandemic and its impacts clouding most of 2020, the rollout of vaccines against COVID-19 is the major highlight of 2021. Over the past few weeks, several pharmaceutical companies have been reporting their developments with regards to their work with their vaccine candidates.

Last week, two companies reported positive data from their trials while one dropped out of the race. Let’s take a look at where these companies stand in terms of vaccine development efforts:

Pfizer – Moderna

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are at the forefront of the fight against COVID-19. The vaccines of both companies were proven to be 95% effective against the virus and are currently being used in several countries across the world.


Novavax (NASDAQ: NVAX) disclosed results from its Phase 3 clinical trial on Thursday which showed that its COVID-19 vaccine candidate NVX-CoV2373 was 89% effective in combating the virus. The vaccine also displayed an efficacy rate of 85.6% against the UK variant strain but the efficacy rate against the South Africa variant was 49.4%. The vaccine can be stored at refrigerator temperatures and can be transported using the existing facilities.

Johnson & Johnson

On Friday, Johnson & Johnson (NYSE: JNJ) announced that its COVID-19 vaccine candidate was 66% effective in preventing moderate to severe COVID-19 infection. The trial, conducted across eight countries, showed different protection levels across regions, with the US showing an efficacy rate of 72% while South Africa showed only 57%.

J&J’s vaccine has the benefit of needing only a single dose, unlike its rivals which need two doses, and it can be stored for two years at a temperature of -20°C and for three months at refrigerator temperatures of 2-8°C. The company plans to file for Emergency Use Authorization in the US in early February.

Eli Lilly

Last week, Eli Lilly and Company (NYSE: LLY) announced results from its Phase 3 BLAZE-1 trial, which showed that the combination of its neutralizing antibodies bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and death by 70%. Bamlanivimab is already authorized in the US for emergency use to treat high-risk patients with mild to moderate COVID-19.


Last week, Merck & Co. (NYSE: MRK) halted the development of its COVID-19 vaccine candidates, V590 and V591, after the Phase 1 clinical trials showed that both candidates displayed inferior immune responses compared to those seen following natural infection as well as those shown by its peers’ products.

Stock performance

Over the past one month, the stocks of these companies have gained/dropped as follows:

Pfizer – down 2%

Moderna – up 45%

Novavax – up 138%

Johnson & Johnson – up 4%

Eli Lilly – up 25%

Merck – down 4%

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Aurora Cannabis (ACB) Earnings: 3Q21 Key Numbers

Aurora Cannabis Inc. (NYSE: ACB) reported third quarter 2021 earnings results today. Total revenues fell 25% year-over-year to CAD55.1 million. Adjusted EBITDA loss amounted to CAD24 million. Cash balance as

Walt Disney (DIS) Q2 revenue down 13%; earnings beat estimates

Media behemoth The Walt Disney Company (NYSE: DIS) reported second-quarter revenues that declined from last year as customers stayed away from theatres and parks due to pandemic-related safety issues and

Three key factors that bode well for Tattooed Chef (TTCF) going forward

Shares of Tattooed Chef Inc. (NASDAQ: TTCF) have gained 57% over the past 12 months but has dropped 25% since the start of this year. The sentiment on the stock

Add Comment
Viewing Highlight